1. From NF-κB to cGAS: An interview with Professor Zhijian James Chen on unraveling innate immunityhLife | 从NF-κB到cGAS陈志坚教授访谈——揭开固有免疫的奥秘通信作者曾文文、Lai Guan Ng、陈志坚、闫群在这次对话中陈志坚教授回顾了他的研究历程从最初对泛素和NF-κB信号的探索到MAVS和cGAS的发现展现了他对细胞信号传导及人类疾病的持久热情。陈教授强调科研工作的关键在于不畏艰难关注具有深远影响而且尚未解决的问题且能坚持不懈。这次交流不仅为有志于科研的年轻学者提供了导师般的视角也凝练了生物医学研究成功之路的精髓。引用Zeng W, Ng LG, Chen ZJ, et al. From NF-κB to cGAS: An interview with Prof. Zhijian James Chen on unraveling innate immunity. hLife 2025; 3: 253–257.2. Induction of translation-suppressive G3BP1 stress granules and interferon-signaling cGAS condensates by transfected plasmid DNAhLife | 美国国家癌症研究所郑志明和Vladimir Majerciak研究团队破译质粒DNA转染激活双重免疫应答机制通信作者Vladimir Majerciak本研究通过脂质体介导的质粒转染实验结合荧光显微成像、siRNA敲低及病毒蛋白共表达等技术揭示了质粒DNA触发宿主天然免疫的双重机制。引用Majerciak V, Zheng ZM. Induction of translation-suppressive G3BP1 stress granules and interferon-signaling cGAS condensates by transfected plasmid DNA. hLife 2024; 3: 21–37.3. Boosting CAR-T cell therapy with CRISPR technologyhLife | CRISPR技术在CAR-T疗法中的应用通信作者邬一谦文章综述CRISPR技术在CAR-T疗法中的应用通过CRISPR可以提高CAR-T疗法的安全性和有效性。引用Yan L, Gao S, Wang X, et al. Boosting CAR-T cell therapy with CRISPR technology. hLife 2024; 2: 380–396.4. Mechanism of microglia-mediated neuroinflammation, associated cognitive dysfunction, and therapeutic updates in Alzheimers diseasehLife | Ashif Iqubal等研究团队阐明小胶质细胞与阿尔茨海默病的神经炎症和认知障碍的关系通信作者Mohammad Kashif Iqubal、Ashif Iqubal本文详细梳理了小胶质细胞激活机制及其与神经炎症和痴呆的关系并介绍了作用于tau蛋白或缓解神经炎症的药物及其临床进展。引用Ghimire A, Rehman SA, Subhani A, et al. Mechanism of microglia mediated neuroinflammation, associated cognitive dysfunction, and therapeutic updates in Alzheimer’s disease. hLife 2025; 3: 64–81.5. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathyhLife | CAR-T细胞治疗点亮慢性格林巴利综合征的治愈希望通信作者施明、崔桂云、郑骏年本文报道了全球首例慢性格林巴利综合征CIDP患者接受嵌合抗原受体工程化T细胞CAR-T细胞治疗后随访1年期的结果系统解析了BCMA-CD19双特异性CAR-T细胞用于治疗难治性/复发性CIDP的可行性、耐受性和疗效深入探讨了CAR-T细胞疗法治疗自身免疫性疾病的广阔前景。引用Zhang W, Liu D, Zhang T, et al. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife 2024; 2: 434–438.6. Microbiota, chronic inflammation, and health: The promise of inflammatome and inflammatomics for precision medicine and health carehLife | 菌群、慢性炎症与健康炎症组学开启精准医疗新时代通信作者Seppo J. Salminen、朱宝利、杨瑞馥本文系统阐述了肠道微生物群通过调控慢性炎症影响肥胖、代谢疾病等全身性疾病的机制开创性地提出“炎症组”和“炎症组学”这两个术语旨在解码菌群失调驱动的慢性炎症并阐明其与疾病的关联。引用Zhang H, Yang Lee BJ, Wang T, et al. Microbiota, chronic inflammation, and health: The promise of inflammatome and inflammatomics for precision medicine and health care. hLife 2025; 3: 307–326.7. Unveiling the multifaceted roles of ISG15 and ISGylation in copper metabolism and cuproptosishLife | 西南大学谢建平研究团队阐述ISG15和ISGylation在铜代谢和铜死亡中的作用通信作者谢建平本文深入探讨了ISG15、ISGylation、铜代谢与铜蛋白凋亡之间的复杂关系旨在强调这些生物过程的参与者在疾病背景下的创新性和重要性。引用Xu J, Zhang Q, Suleiman IM, et al. Unveiling the multifaceted roles of ISG15 and ISGylation in copper metabolism and cuproptosis. hLife 2025; 3: 498–500.8. Candida albicans overgrowth impairs anti-PD-1 immunotherapy in oral tumor-bearing mice通信作者闫志敏Candida albicans is one of the most common fungi living in the human gut and oral cavity, and shows associations with the development and prognosis of multiple types of cancer. Our previous study found that C. albicans overgrowth promoted oral cancer development and impaired anti-programmed cell death protein-1 (PD-1) treatment in mice. However, it is unclear whether different levels of C. albicans have different effects on the efficacy of anti-PD-1 therapy for oral cancer. Additionally, whether gut overgrowth of C. albicans influences anti-PD-1 therapy for distant tumor sites is also unknown.引用Wang X, Zhang X, Wu S, et al. Candida albicans overgrowth impairs anti-PD-1 immunotherapy in oral tumor-bearing mice. hLife 2025; 3: 407–409.9. Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip bloodhLife | 一滴指尖血打造快速便捷的免疫检测新模式通信作者谭骁天、柴语娟、郑海荣、范旭东、谢良志、曹云龙、杨慧本研究团队成功研发出一种便携式微流控化学发光免疫分析平台Tip Optofluidic Immunoassay简称TOI。只需1微升指尖血研究人员就能利用TOI平台在40分钟内完成抗体结合能力和中和能力等多维度免疫指标的快速定量评估为传染病防控与免疫防护能力监测提供了先进技术手段。引用Tan X, Chai Y, Li R, et al. Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood. hLife 2025; 3: 338–356.10. Advances in the pathogenic, genetic and immunological studies of leprosyhLife | 麻风──一个从未消失的疾病通信作者刘红、张福仁本文综述了麻风病因学、免疫遗传学研究现状呈现了人类对麻风的认识由“无知”导致“谈麻色变”到发现麻风菌-开启化学治疗时代进而发现“导致麻风危害发生”的内因-遗传风险因子开启麻风精准防治新阶段。引用Mi Z, Liu H, Zhang F. Advances in the pathogenic, genetic and immunological studies of leprosy. hLife 2024; 2: 6–17.11. Enabling manufacture and access to advanced therapy medicinal products in low- and middle-income countrieshLife | 巴西探索新模式突破高价药困局大幅降低癌症与罕见病治疗成本通信作者Antonio Carlos Campos de Carvalho巴西正在通过创新、高效且经济的生产与分发模式在提升先进治疗用药ATMPs可及性方面取得重大进展。这些举措由隶属于巴西联邦政府的奥斯瓦尔多·克鲁兹基金会Fiocruz主导旨在大幅降低癌症和罕见遗传病等疾病治疗的高昂费用减轻医疗系统和政府财政的压力。引用Campos de Carvalho AC, Sachetti CG, Krieger MA. Enabling manufacture and access to advanced therapy medicinal products in low- and middle-income countries. hLife 2025; 3: 521–523.12. The 2025 Nobel Prize in Physiology or Medicine: The Treg, FoxP3, and STAT-regulated immune network通信作者傅新元引用Fu XY. The 2025 Nobel Prize in Physiology or Medicine: The Treg, FoxP3, and STAT-regulated immune network. hLife 2025; 3: 573–575.13. Harnessing allogeneic CAR-T cell therapy for autoimmune conditions通信作者徐沪济闫群Chimeric antigen receptor-T (CAR-T) cell therapy has revolutionized cancer treatment, yet its application to autoimmune diseases remains in its infancy. In 2024, Professor Huji Xu and his colleagues achieved a groundbreaking milestone in allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. In this dialogue, Professor Xu elaborated on the rationale and development of allogeneic CAR-T therapy as a cost-effective, scalable alternative to autologous approaches. By utilizing multiplex genome-edited CD19-targeted CAR-T cells derived from healthy donors, his team aims to address critical challenges in manufacturing, accessibility, and long-term efficacy. Professor Xu also discussed strategies for cost reduction, regulatory hurdles, and the broader implications for immunotherapy. Drawing on his extensive experience, he envisions allogeneic CAR-T therapy emerging as a transformative treatment for autoimmune diseases, with the potential to achieve widespread accessibility and profound clinical impact.引用Yan Q, Xu H. Harnessing allogeneic CAR-T cell therapy for autoimmune conditions. hLife 2025; 3: 159–161.
hLife Collection | Immunology (Part Ⅱ)
1. From NF-κB to cGAS: An interview with Professor Zhijian James Chen on unraveling innate immunityhLife | 从NF-κB到cGAS陈志坚教授访谈——揭开固有免疫的奥秘通信作者曾文文、Lai Guan Ng、陈志坚、闫群在这次对话中陈志坚教授回顾了他的研究历程从最初对泛素和NF-κB信号的探索到MAVS和cGAS的发现展现了他对细胞信号传导及人类疾病的持久热情。陈教授强调科研工作的关键在于不畏艰难关注具有深远影响而且尚未解决的问题且能坚持不懈。这次交流不仅为有志于科研的年轻学者提供了导师般的视角也凝练了生物医学研究成功之路的精髓。引用Zeng W, Ng LG, Chen ZJ, et al. From NF-κB to cGAS: An interview with Prof. Zhijian James Chen on unraveling innate immunity. hLife 2025; 3: 253–257.2. Induction of translation-suppressive G3BP1 stress granules and interferon-signaling cGAS condensates by transfected plasmid DNAhLife | 美国国家癌症研究所郑志明和Vladimir Majerciak研究团队破译质粒DNA转染激活双重免疫应答机制通信作者Vladimir Majerciak本研究通过脂质体介导的质粒转染实验结合荧光显微成像、siRNA敲低及病毒蛋白共表达等技术揭示了质粒DNA触发宿主天然免疫的双重机制。引用Majerciak V, Zheng ZM. Induction of translation-suppressive G3BP1 stress granules and interferon-signaling cGAS condensates by transfected plasmid DNA. hLife 2024; 3: 21–37.3. Boosting CAR-T cell therapy with CRISPR technologyhLife | CRISPR技术在CAR-T疗法中的应用通信作者邬一谦文章综述CRISPR技术在CAR-T疗法中的应用通过CRISPR可以提高CAR-T疗法的安全性和有效性。引用Yan L, Gao S, Wang X, et al. Boosting CAR-T cell therapy with CRISPR technology. hLife 2024; 2: 380–396.4. Mechanism of microglia-mediated neuroinflammation, associated cognitive dysfunction, and therapeutic updates in Alzheimers diseasehLife | Ashif Iqubal等研究团队阐明小胶质细胞与阿尔茨海默病的神经炎症和认知障碍的关系通信作者Mohammad Kashif Iqubal、Ashif Iqubal本文详细梳理了小胶质细胞激活机制及其与神经炎症和痴呆的关系并介绍了作用于tau蛋白或缓解神经炎症的药物及其临床进展。引用Ghimire A, Rehman SA, Subhani A, et al. Mechanism of microglia mediated neuroinflammation, associated cognitive dysfunction, and therapeutic updates in Alzheimer’s disease. hLife 2025; 3: 64–81.5. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathyhLife | CAR-T细胞治疗点亮慢性格林巴利综合征的治愈希望通信作者施明、崔桂云、郑骏年本文报道了全球首例慢性格林巴利综合征CIDP患者接受嵌合抗原受体工程化T细胞CAR-T细胞治疗后随访1年期的结果系统解析了BCMA-CD19双特异性CAR-T细胞用于治疗难治性/复发性CIDP的可行性、耐受性和疗效深入探讨了CAR-T细胞疗法治疗自身免疫性疾病的广阔前景。引用Zhang W, Liu D, Zhang T, et al. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife 2024; 2: 434–438.6. Microbiota, chronic inflammation, and health: The promise of inflammatome and inflammatomics for precision medicine and health carehLife | 菌群、慢性炎症与健康炎症组学开启精准医疗新时代通信作者Seppo J. Salminen、朱宝利、杨瑞馥本文系统阐述了肠道微生物群通过调控慢性炎症影响肥胖、代谢疾病等全身性疾病的机制开创性地提出“炎症组”和“炎症组学”这两个术语旨在解码菌群失调驱动的慢性炎症并阐明其与疾病的关联。引用Zhang H, Yang Lee BJ, Wang T, et al. Microbiota, chronic inflammation, and health: The promise of inflammatome and inflammatomics for precision medicine and health care. hLife 2025; 3: 307–326.7. Unveiling the multifaceted roles of ISG15 and ISGylation in copper metabolism and cuproptosishLife | 西南大学谢建平研究团队阐述ISG15和ISGylation在铜代谢和铜死亡中的作用通信作者谢建平本文深入探讨了ISG15、ISGylation、铜代谢与铜蛋白凋亡之间的复杂关系旨在强调这些生物过程的参与者在疾病背景下的创新性和重要性。引用Xu J, Zhang Q, Suleiman IM, et al. Unveiling the multifaceted roles of ISG15 and ISGylation in copper metabolism and cuproptosis. hLife 2025; 3: 498–500.8. Candida albicans overgrowth impairs anti-PD-1 immunotherapy in oral tumor-bearing mice通信作者闫志敏Candida albicans is one of the most common fungi living in the human gut and oral cavity, and shows associations with the development and prognosis of multiple types of cancer. Our previous study found that C. albicans overgrowth promoted oral cancer development and impaired anti-programmed cell death protein-1 (PD-1) treatment in mice. However, it is unclear whether different levels of C. albicans have different effects on the efficacy of anti-PD-1 therapy for oral cancer. Additionally, whether gut overgrowth of C. albicans influences anti-PD-1 therapy for distant tumor sites is also unknown.引用Wang X, Zhang X, Wu S, et al. Candida albicans overgrowth impairs anti-PD-1 immunotherapy in oral tumor-bearing mice. hLife 2025; 3: 407–409.9. Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip bloodhLife | 一滴指尖血打造快速便捷的免疫检测新模式通信作者谭骁天、柴语娟、郑海荣、范旭东、谢良志、曹云龙、杨慧本研究团队成功研发出一种便携式微流控化学发光免疫分析平台Tip Optofluidic Immunoassay简称TOI。只需1微升指尖血研究人员就能利用TOI平台在40分钟内完成抗体结合能力和中和能力等多维度免疫指标的快速定量评估为传染病防控与免疫防护能力监测提供了先进技术手段。引用Tan X, Chai Y, Li R, et al. Tip optofluidic immunoassay: Evaluating COVID-19 antibody protection with 1 μL fingertip blood. hLife 2025; 3: 338–356.10. Advances in the pathogenic, genetic and immunological studies of leprosyhLife | 麻风──一个从未消失的疾病通信作者刘红、张福仁本文综述了麻风病因学、免疫遗传学研究现状呈现了人类对麻风的认识由“无知”导致“谈麻色变”到发现麻风菌-开启化学治疗时代进而发现“导致麻风危害发生”的内因-遗传风险因子开启麻风精准防治新阶段。引用Mi Z, Liu H, Zhang F. Advances in the pathogenic, genetic and immunological studies of leprosy. hLife 2024; 2: 6–17.11. Enabling manufacture and access to advanced therapy medicinal products in low- and middle-income countrieshLife | 巴西探索新模式突破高价药困局大幅降低癌症与罕见病治疗成本通信作者Antonio Carlos Campos de Carvalho巴西正在通过创新、高效且经济的生产与分发模式在提升先进治疗用药ATMPs可及性方面取得重大进展。这些举措由隶属于巴西联邦政府的奥斯瓦尔多·克鲁兹基金会Fiocruz主导旨在大幅降低癌症和罕见遗传病等疾病治疗的高昂费用减轻医疗系统和政府财政的压力。引用Campos de Carvalho AC, Sachetti CG, Krieger MA. Enabling manufacture and access to advanced therapy medicinal products in low- and middle-income countries. hLife 2025; 3: 521–523.12. The 2025 Nobel Prize in Physiology or Medicine: The Treg, FoxP3, and STAT-regulated immune network通信作者傅新元引用Fu XY. The 2025 Nobel Prize in Physiology or Medicine: The Treg, FoxP3, and STAT-regulated immune network. hLife 2025; 3: 573–575.13. Harnessing allogeneic CAR-T cell therapy for autoimmune conditions通信作者徐沪济闫群Chimeric antigen receptor-T (CAR-T) cell therapy has revolutionized cancer treatment, yet its application to autoimmune diseases remains in its infancy. In 2024, Professor Huji Xu and his colleagues achieved a groundbreaking milestone in allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. In this dialogue, Professor Xu elaborated on the rationale and development of allogeneic CAR-T therapy as a cost-effective, scalable alternative to autologous approaches. By utilizing multiplex genome-edited CD19-targeted CAR-T cells derived from healthy donors, his team aims to address critical challenges in manufacturing, accessibility, and long-term efficacy. Professor Xu also discussed strategies for cost reduction, regulatory hurdles, and the broader implications for immunotherapy. Drawing on his extensive experience, he envisions allogeneic CAR-T therapy emerging as a transformative treatment for autoimmune diseases, with the potential to achieve widespread accessibility and profound clinical impact.引用Yan Q, Xu H. Harnessing allogeneic CAR-T cell therapy for autoimmune conditions. hLife 2025; 3: 159–161.
